Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
450
Clinical Trial Start Date
2006
0Primary Completion Date
2010
0Study Completion Date
2010
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Basic Science0
Intervention Type
Device0
Drug0
Interventional Trial Phase
Phase 20
Phase 10
Official Name
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease0
Last Updated
August 19, 2011
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
MRI0
Primovist® 0,25 mmol/ml solution for injection0
Study summary
The objective of the study is to assess the hepatic uptake of Primovist® after intravenous administration of 25 µmol/kg body weight in 56 healthy volunteers and in 60 patients with a liver disease in dependence on the OATP1B1- and OATP1B3-genotype.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
